PHS 2024-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed) | PA 24 247

Opportunity Information: Apply for PA 24 247

The PHS 2024-2 Omnibus Solicitation is a National Institutes of Health (NIH) parent funding opportunity (PA-24-247) that invites eligible U.S. small businesses to apply for Small Business Technology Transfer (STTR) awards using the R41 (Phase I) and R42 (Phase II) grant mechanisms. The purpose is to support early-stage research and development (R and D) projects where a small business works in formal partnership with a research institution, combining commercialization-focused product development with the scientific strengths of the nonprofit or academic research environment. The solicitation is considered an omnibus or parent announcement, meaning it is designed to cover a broad range of NIH-relevant topic areas rather than a single narrowly defined project theme. Applicants are expected to align their proposed work with the missions of the participating NIH awarding components and to select an appropriate topic area referenced in the NIH/CDC/FDA SBIR/STTR Program Descriptions and Research Topics.

This opportunity is specifically labeled “Clinical Trial Not Allowed,” which is a major boundary condition for project design. Applications must not propose clinical trials, and they should be structured around non-clinical research activities such as technology development, feasibility testing, prototyping, assay development, preclinical validation, computational methods, device engineering, or other translational R and D steps that stop short of conducting a clinical trial. In practice, this means the work plan should focus on generating technical proof-of-concept, performance data, and readiness milestones that de-risk the technology and position it for future regulatory, partnering, or follow-on funding pathways, without enrolling human participants into a clinical trial under this award.

Eligibility is centered on U.S. small businesses. Non-domestic (non-U.S.) entities are not eligible to apply, and non-domestic components of U.S. organizations are also not eligible to apply. However, “foreign components,” as defined in the NIH Grants Policy Statement, may be allowable in some cases, which typically refers to discrete project elements performed outside the United States when there is a strong justification that the work cannot be reasonably performed domestically or that a unique resource or expertise is needed. Even when foreign components are permitted, the applicant organization must still be an eligible U.S. small business, and the overall project must remain compliant with NIH policy requirements for justification, oversight, and documentation.

From an administrative and classification standpoint, the opportunity is a discretionary grant program (Funding Instrument Type: Grant) managed by NIH, with an activity scope spanning multiple public purpose areas including health as well as related categories such as education, environment, food and nutrition, and income security/social services, reflecting the breadth of NIH’s participating institutes and centers and the wide set of problem areas that biomedical and behavioral technologies can impact. The solicitation is associated with many CFDA (Assistance Listing) numbers, indicating that multiple NIH components and program areas may use this parent STTR vehicle to support projects. The posting shows an original closing date of 2025-04-05, and it was created on 2024-07-03. While the listing does not provide an award ceiling or expected number of awards in the excerpt provided, STTR awards under R41/R42 are generally milestone-driven, with Phase I commonly used to establish feasibility and Phase II used to continue development toward commercialization readiness, subject to NIH-specific budget caps, program priorities, and review outcomes.

Conceptually, this NOFO is aimed at small businesses that have a credible path to turning R and D into a product, platform, or service that advances NIH mission needs, while leveraging a formal collaboration with a research institution. Competitive applications typically make the public health or scientific need clear, define measurable technical milestones, and describe a realistic commercialization strategy, while also demonstrating that the team has the expertise, facilities, and partnership structure to execute the proposed work. Applicants are expected to ensure their topic choice and scientific aims fit within the NIH component missions identified under the omnibus topics list and to keep the project clearly outside the scope of a clinical trial for this particular parent announcement.

• The National Institutes of Health in the education, environment, food and nutrition, health, income security and social services sector is offering a public funding opportunity titled "PHS 2024-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.113, 93.121, 93.172, 93.173, 93.213, 93.233, 93.242, 93.273, 93.279, 93.286, 93.307, 93.350, 93.351, 93.361, 93.393, 93.394, 93.395, 93.837, 93.838, 93.839, 93.840, 93.846, 93.847, 93.853, 93.855, 93.859, 93.865, 93.866, 93.867, 93.879.
• This funding opportunity was created on 2024-07-03.
• Applicants must submit their applications by 2025-04-05. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: Small businesses.

Apply for PA 24 247

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: